---
figid: PMC7911620__pharmaceutics-13-00142-g001
figtitle: TLR-activating adjuvants and the induced signalling pathway
organisms:
- NA
pmcid: PMC7911620
filename: pharmaceutics-13-00142-g001.jpg
figlink: pmc/articles/PMC7911620/figure/pharmaceutics-13-00142-f001/
number: F1
caption: 'TLR-activating adjuvants and the induced signalling pathway. Cell surface
  TLRs (TLR1, TLR2, TLR4, TLR5, TLR6) and intracellular (endosomal) TLRs (TLR3, TLR7,
  TLR8, TLR9) are the targets of the illustrated adjuvants. Upon binding of the appropriate
  adjuvant by the LRR domain, TLRs recruit TIR domain-containing adaptor proteins
  like MyD88 and TRIF, which activate NF-κB signalling, MAP kinases (not shown) and
  IRFs) (e.g., IRF3, IRF7 mediated type I IFN responses). This initiates the expression
  of pro-inflammatory cytokines such as TNF-α, IL-6, IFN-γ or the type I interferons
  IFN-α and IFN-β. The TIR domain-containing adapter proteins in the figure are colour-coded
  to show whether the signalling of each TLR is MyD88- or TRIF-dependent. Abbreviations:
  TLR (Toll-like receptor), LRR (leucine-rich repeat), TIR (Toll-Interleukin receptor),
  MyD88 (myeloid differentiation factor 88), TRIF (TIR domain-containing adaptor protein
  inducing IFNβ), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B
  cells), MAP (mitogen-activated protein), IRF (Interferon Regulatory Factor), IFN
  (Interferon), TNF-α (tumour necrosis factor-alpha), IL (Interleukin); Created with
  BioRender.com.'
papertitle: TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases.
reftext: Marina Luchner, et al. Pharmaceutics. 2021 Feb;13(2):142.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9456281
figid_alias: PMC7911620__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7911620__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7911620__pharmaceutics-13-00142-g001.html
  '@type': Dataset
  description: 'TLR-activating adjuvants and the induced signalling pathway. Cell
    surface TLRs (TLR1, TLR2, TLR4, TLR5, TLR6) and intracellular (endosomal) TLRs
    (TLR3, TLR7, TLR8, TLR9) are the targets of the illustrated adjuvants. Upon binding
    of the appropriate adjuvant by the LRR domain, TLRs recruit TIR domain-containing
    adaptor proteins like MyD88 and TRIF, which activate NF-κB signalling, MAP kinases
    (not shown) and IRFs) (e.g., IRF3, IRF7 mediated type I IFN responses). This initiates
    the expression of pro-inflammatory cytokines such as TNF-α, IL-6, IFN-γ or the
    type I interferons IFN-α and IFN-β. The TIR domain-containing adapter proteins
    in the figure are colour-coded to show whether the signalling of each TLR is MyD88-
    or TRIF-dependent. Abbreviations: TLR (Toll-like receptor), LRR (leucine-rich
    repeat), TIR (Toll-Interleukin receptor), MyD88 (myeloid differentiation factor
    88), TRIF (TIR domain-containing adaptor protein inducing IFNβ), NF-κB (nuclear
    factor kappa-light-chain-enhancer of activated B cells), MAP (mitogen-activated
    protein), IRF (Interferon Regulatory Factor), IFN (Interferon), TNF-α (tumour
    necrosis factor-alpha), IL (Interleukin); Created with BioRender.com.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MPL
  - TLR2
  - TLR1
  - TLR5
  - TLR4
  - MYD88
  - TRIM69
  - TICAM1
  - TLR3
  - TLR9
  - TLR7
  - TLR8
  - NFKB1
  - IL6
  - TNF
  - IL1B
  - CCL2
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - CCL3
  - CD86
  - CD80
  - IFNK
  - IFNW1
  - IFNA1
  - IFNA2
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA17
  - IFNA21
  - IFNB1
  - CpG
  - Poly
---
